The Speciality Medicines IPO will be open for public subscription from Friday, March 20, 2026, to Tuesday, March 24, 2026. The issue is a 100% fresh issue of 2.35 million equity shares. Retail investors can participate with a minimum investment of ₹2,48,000 (covering 2 lots of 1,000 shares each) at the upper price band. The shares are proposed to be listed on the BSE SME platform.
The company operates a unique dual-business model:
-
Contract Manufacturing: Coordinating with Indian manufacturers for finished formulations tailored for international markets.
-
Marketing & Distribution: Sourcing and supplying specialty drugs (injectables, oral solutions, etc.) to over 20 states in India and 35+ countries.
Financial Highlights:
Speciality Medicines has reported a massive spike in profitability recently:
-
Revenue: Scaled from ₹27.66 crore in FY24 to ₹58.54 crore in FY25.
-
Profit After Tax (PAT): Witnessed a sharp jump from ₹2.93 crore in FY24 to ₹8.61 crore in FY25.
-
Asset Growth: Total assets nearly doubled in one year, reaching ₹39.98 crore by March 2025.
The IPO proceeds are strategically allocated toward:
-
₹13.31 crore for setting up a dedicated Research & Development (R&D) Center.
-
₹12.00 crore for working capital to support its intensive trading cycles.
-
₹2.89 crore for international product registrations in target markets like Peru and Uganda.
Key IPO Details & Timetable
| Feature | Details |
| Price Band | ₹117 – ₹124 per share |
| Min. Investment (Retail) | ₹2,48,000 (2,000 Shares / 2 Lots) |
| Total Issue Size | ₹29.14 Crore (Fresh Issue) |
| Public Open Date | March 20, 2026 (Friday) |
| Public Close Date | March 24, 2026 (Tuesday) |
| Allotment Date | March 25, 2026 |
| Tentative Listing | March 30, 2026 (BSE SME) |
Important Real News & Today’s Insights (March 18)
-
Grey Market Premium (GMP): As of today, the GMP is trading at ₹0 (Flat). Despite the company's strong profit growth, the grey market is exhibiting caution, likely waiting to see the subscription intensity from institutional buyers on Friday.
-
The "Sustainability" Debate: Market analysts (including reviews on Chittorgarh) have pointed out that the sudden jump in PAT from ₹2.9cr to ₹8.6cr within a single year has "raised eyebrows." Today's investor discussions are focused on whether this performance is sustainable or if it was "boosted" specifically for the IPO valuation.
-
Working Capital Warning: The company’s working capital requirement has surged from roughly ₹7.4 crore to ₹31.2 crore in FY25. This highlights a capital-intensive business model where cash is frequently locked in inventory and receivables.
-
International Moat: A significant positive note in today's news is that as of early 2026, the company has 54 products currently in the registration process across 5 countries. Success in these registrations could provide a multi-year revenue cushion.
-
Valuation Comparison: At the upper cap of ₹124, the IPO is priced at a P/E that appears lucrative compared to listed peers like Remus Pharmaceuticals (P/E ~23x) and Mono Pharmacare (P/E ~24x), provided the FY25 earnings are treated as the base.